플라스미드 DNA 제조 시장 규모, 점유율, 동향 분석 보고서 : 질병별, 등급별, 용도별, 개발 단계별, 지역별, 부문별 예측(2025-2030년)

Plasmid DNA Manufacturing Market Growth & Trends:

The global plasmid DNA manufacturing market size is expected to reach USD 6.70 billion by 2030, expanding at a CAGR of 21.44% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of chronic diseases, combined with the wide application scope of plasmid DNA in the healthcare industry is expected to drive the industry growth. Plasmid DNA can be used directly for therapeutic applications, such as the production of vaccine antigens or gene therapy. Moreover, it can be utilized for various research purposes, such as gene cloning, gene mapping, etc. The rising number of patients choosing gene therapy is expected to drive industry growth in the coming years.

According to clinicaltrials.gov, the number of cell & gene therapies across global pipeline programs (Phase I to Phase III trials) increased from 289 in 2018 to 327 in 2022. Furthermore, the U.S. FDA provides constant support for innovations in the advanced therapy arena via several policies concerning product manufacturing. With increased cell and gene therapy products, the industry will see an increased need for manufacturing plasmid DNA on a larger scale. The COVID-19 pandemic is anticipated to positively impact industry growth. For instance, in September 2021, India approved the first COVID-19 DNA vaccine. It is the world's first COVID-19 DNA vaccine manufactured in partnership with DBT-BIRAC as part of Mission COVID Suraksha.

Circular DNA is used in India's ZyCoV-D vaccination to protect against COVID-19 infection. Furthermore, key entities in the global industry are undertaking various strategic initiatives to strengthen their market presence, which is also expected to propel growth. For instance, in June 2022, BioCina announced the expansion of the production of plasmid DNA in a new dedicated GMP suite to its offering of CDMO services. The suite has a single-use fermentation capacity of up to 300 L and appropriately scaled downstream processing machinery.

Plasmid DNA Manufacturing Market Report Highlights:

• MP-grade plasmid DNA manufacturing dominated the market in 2024 with a share of 86.29% and is expected to grow at the fastest CAGR over the forecast period.
• The clinical therapeutics segment held the largest market share of 54.6% in 2024. Plasmid DNA is currently increasing in importance for clinical research applications in genetic vaccination and gene therapy.
• The cell & gene therapy segment held the largest market share of 54.4% in 2024. This high share can be attributed to the fact that gene therapy is broadly applied in the treatment of several inherited and genetic diseases.
• The cancer segment held the largest market share of 40.0% in 2024 and is expected to witness the fastest CAGR from 2025 to 2030.
• The North America Plasmid DNA manufacturing market held the largest revenue share of 43.43% of the global market in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Grade
  • 1.2.2. Development Phase
  • 1.2.3. Application
  • 1.2.4. Disease
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
  • 1.9.1. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Increasing number of patients opting for gene therapy
  • 3.3.2. Robust pipeline for gene therapies
  • 3.3.3. Highly competitive market and various strategies undertaken by market players
  • 3.3.4. Increasing demand for plasmid DNA in various medical therapies
• 3.4. Market Restraint Analysis
  • 3.4.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy
• 3.5. Business Environment Analysis
  • 3.5.1. PESTEL Analysis
  • 3.5.2. Porter's Five Forces Analysis
  • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Grade Business Analysis

• 4.1. Segment Dashboard
• 4.2. Global Plasmid DNA Manufacturing Market Movement Analysis
• 4.3. Global Plasmid DNA Manufacturing Market Size & Trend Analysis, by Grade, 2018 to 2030 (USD Million)
• 4.4. R&D Grade
  • 4.4.1. R&D Grade Market, 2018 - 2030 (USD Million)
  • 4.4.2. Viral Vector Development
    • 4.4.2.1. Viral Vector Development Market, 2018 - 2030 (USD Million)
    • 4.4.2.2. AAV
      • 4.4.2.2.1. AAV Market, 2018 - 2030 (USD Million)
    • 4.4.2.3. Lentivirus
      • 4.4.2.3.1. Lentivirus Market, 2018 - 2030 (USD Million)
    • 4.4.2.4. Adenovirus
      • 4.4.2.4.1. Adenovirus Market, 2018 - 2030 (USD Million)
    • 4.4.2.5. Retrovirus
      • 4.4.2.5.1. Retrovirus Market, 2018 - 2030 (USD Million)
    • 4.4.2.6. Others
      • 4.4.2.6.1. Others Market, 2018 - 2030 (USD Million)
  • 4.4.3. mRNA Development
    • 4.4.3.1. mRNA Development Market, 2018 - 2030 (USD Million)
  • 4.4.4. Antibody Development
    • 4.4.4.1. Antibody Development Market, 2018 - 2030 (USD Million)
  • 4.4.5. DNA Vaccine Development
    • 4.4.5.1. DNA Vaccine Development Market, 2018 - 2030 (USD Million)
  • 4.4.6. Others
    • 4.4.6.1. Others Market, 2018 - 2030 (USD Million)
• 4.5. GMP Grade
  • 4.5.1. GMP Grade Market, 2018 - 2030 (USD Million)

Chapter 5. Development Phase Business Analysis

• 5.1. Segment Dashboard
• 5.2. Global Plasmid DNA Manufacturing Market Movement Analysis
• 5.3. Global Plasmid DNA Manufacturing Market Size & Trend Analysis, by Development Phase, 2018 to 2030 (USD Million)
• 5.4. Pre-Clinical Therapeutics
  • 5.4.1. Pre-Clinical Therapeutics Market, 2018 - 2030 (USD Million)
• 5.5. Clinical Therapeutics
  • 5.5.1. Clinical Therapeutics Market, 2018 - 2030 (USD Million)
• 5.6. Marketed Therapeutics
  • 5.6.1. Marketed Therapeutics Market, 2018 - 2030 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. Segment Dashboard
• 6.2. Global Plasmid DNA Manufacturing Market Movement Analysis
• 6.3. Global Plasmid DNA Manufacturing Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 6.4. DNA Vaccines
  • 6.4.1. DNA Vaccines Market, 2018 - 2030 (USD Million)
• 6.5. Cell & Gene Therapy
  • 6.5.1. Cell & Gene Therapy Market, 2018 - 2030 (USD Million)
• 6.6. Immunotherapy
  • 6.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Disease Business Analysis

• 7.1. Segment Dashboard
• 7.2. Global Plasmid DNA Manufacturing Market Movement Analysis
• 7.3. Global Plasmid DNA Manufacturing Market Size & Trend Analysis, by Disease, 2018 to 2030 (USD Million)
• 7.4. Infectious Disease
  • 7.4.1. Infectious Disease Market, 2018 - 2030 (USD Million)
• 7.5. Cancer
  • 7.5.1. Cancer Market, 2018 - 2030 (USD Million)
• 7.6. Genetic Disorder
  • 7.6.1. Genetic Disorder Market, 2018 - 2030 (USD Million)
• 7.7. Others
  • 7.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Estimates & Trend Analysis by Grade, Development Phase, Disease, & Application

• 8.1. Regional Market Dashboard
• 8.2. Global Plasmid DNA Manufacturing Market Share By Region, 2024 & 2030
• 8.3. North America
  • 8.3.1. North America Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.3.2. U.S.
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Target Disease Prevalence
    • 8.3.2.5. U.S. Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Target Disease Prevalence
    • 8.3.3.5. Canada Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Target Disease Prevalence
    • 8.3.4.5. Mexico Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Target Disease Prevalence
    • 8.4.2.5. Germany Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.3. UK
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Target Disease Prevalence
    • 8.4.3.5. UK Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Target Disease Prevalence
    • 8.4.4.5. France Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Target Disease Prevalence
    • 8.4.5.5. Italy Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Target Disease Prevalence
    • 8.4.6.5. Spain Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Target Disease Prevalence
    • 8.4.7.5. Denmark Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Target Disease Prevalence
    • 8.4.8.5. Sweden Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Target Disease Prevalence
    • 8.4.9.5. Norway Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Target Disease Prevalence
    • 8.5.2.5. Japan Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Target Disease Prevalence
    • 8.5.3.5. China Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Target Disease Prevalence
    • 8.5.4.5. India Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Target Disease Prevalence
    • 8.5.5.5. South Korea Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.5.6. Australia
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Target Disease Prevalence
    • 8.5.6.5. Australia Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.5.7. Thailand
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Target Disease Prevalence
    • 8.5.7.5. Thailand Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Target Disease Prevalence
    • 8.6.2.5. Brazil Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Target Disease Prevalence
    • 8.6.3.5. Argentina Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Target Disease Prevalence
    • 8.7.2.5. South Africa Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Target Disease Prevalence
    • 8.7.3.5. Saudi Arabia Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Target Disease Prevalence
    • 8.7.4.5. UAE Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Target Disease Prevalence
    • 8.7.5.5. Kuwait Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Categorization
• 9.2. Company Market Position Analysis, 2024
• 9.3. Participant's Overview
  • 9.3.1. Charles River Laboratories
    • 9.3.1.1. Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Danaher
    • 9.3.2.1. Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. VGXI, Inc.
    • 9.3.3.1. Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Kaneka Corp.
    • 9.3.4.1. Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Lonza
    • 9.3.5.1. Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Nature Technology
    • 9.3.6.1. Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Cell and Gene Therapy Catapult
    • 9.3.7.1. Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Eurofins Genomics
    • 9.3.8.1. Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Luminous BioSciences, LLC
    • 9.3.9.1. Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Akron Biotech
    • 9.3.10.1. Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product Benchmarking
    • 9.3.10.4. Strategic Initiatives